The effect of pregnancy and lactation on pituitary prolactin-secreting tumours.
Management of the amenorrhoea-galactorrhoea syndrome due to pituitary tumour is still controversial. However, in cases of pituitary prolactin-producing adenomas, ovulation and pregnancy are readily induced medically with bromocriptine. In our series of 14 patients conception occurred in all cases within 6 months of treatment. All of the 14 women had uneventful full term pregnancies and normal infants. Neither neurological nor visual symptoms appeared in these patients during their pregnancies. Lactation had no apparent effect on the growth of the pituitary tumour since radiological and neurological evaluations were unchanged. Prolactin levels for each patient following the termination of pregnancy and breast feeding were apparently diminished or similar to the prolactin levels obtained prior to treatment. This finding could add to the evidence that probably there was no further growth of the pituitary tumour. Three of the 14 women have had a second pregnancy without any complications. It is recommended that patients with microadenomas can be allowed to become pregnant on bromocriptine alone, provided that they are carefully supervised during pregnancy.
D000236:Adenoma / Q000150:complications* / Q000188:drug therapy / Q000378:metabolism; D000328:Adult; D000568:Amenorrhea / Q000188:drug therapy / Q000209:etiology*; D001971:Bromocriptine / Q000627:therapeutic use*; D005260:Female; D005500:Follow-Up Studies; D005687:Galactorrhea / Q000188:drug therapy / Q000209:etiology*; D006801:Humans; D007231:Infant, Newborn; D007774:Lactation; D007775:Lactation Disorders / Q000209:etiology*; D010911:Pituitary Neoplasms / Q000150:complications* / Q000188:drug therapy / Q000378:metabolism; D011247:Pregnancy; D011248:Pregnancy Complications / Q000503:physiopathology*; D011388:Prolactin / Q000097:blood / Q000378:metabolism*
D001971:Bromocriptine; D011388:Prolactin